Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) has shared an update.
Neurizon Therapeutics has issued 9.5 million fully paid ordinary shares to its directors at $0.08 per share as part of their participation in the company’s December 2025 placement, a move previously approved by shareholders at a February 2026 general meeting. The company confirmed the shares were issued without a prospectus under Australian Corporations Act provisions, stated it remains compliant with its continuous disclosure and reporting obligations, and noted there is no excluded information, thereby supporting secondary trading of the new shares and reinforcing governance transparency for investors.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead investigational drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis (ALS), with a strategy to accelerate patient access while exploring broader neurodegenerative indications through international collaborations and clinical programs.
Average Trading Volume: 639,596
Technical Sentiment Signal: Sell
Current Market Cap: A$55.89M
For detailed information about NUZ stock, go to TipRanks’ Stock Analysis page.